Spero Therapeutics (SPRO:NASDAQ) Annual Reports & Investor Relations Material

Overview

Cambridge-based clinical-stage biopharmaceutical company Spero Therapeutics, Inc. is focusing its efforts on the challenging area of multi-drug resistant bacterial infections and rare diseases. The company's current product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating complicated urinary tract infections in adults, SPR206, a direct-acting, IV-administered agent designed to tackle MDR Gram-negative bacterial infections in hospital, and SPR720, a novel oral antibiotic that could be used as a treatment for non-tuberculous mycobacterial pulmonary disease. Tebipenem HBr is supported by a license agreement with Meiji Seika Pharma Co., Everest Medicines has licensed the development, manufacture, and commercialization rights for SPR206 in China, South Korea, and Southeast Asian countries, whilst Bill & Melinda Gates Medical Research Institute is partnering on the development of SPR720 to fight lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement has been signed with Vertex Pharmaceuticals Incorporated for patents relating to SPR719, an active metabolite of SPR720. Spero Therapeutics, Inc. was established in 2013 and is headquartered in Cambridge, Massachusetts.

Frequently Asked Questions

What is Spero Therapeutics's ticker?

Spero Therapeutics's ticker is SPRO

What exchange is Spero Therapeutics traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Spero Therapeutics's headquarters?

They are based in Cambridge, Massachusetts

How many employees does Spero Therapeutics have?

There are 51-200 employees working at Spero Therapeutics

What is Spero Therapeutics's website?

It is sperotherapeutics.com

What type of sector is Spero Therapeutics?

Spero Therapeutics is in the Healthcare sector

What type of industry is Spero Therapeutics?

Spero Therapeutics is in the Biotechnology industry

Who are Spero Therapeutics's peers and competitors?

The following five companies are Spero Therapeutics's industry peers:

- Cancer Genetics, Inc.

- Merus

- Xbiotech Inc

- Molecular Templates, Inc.

- Codexis